125 related articles for article (PubMed ID: 36083216)
21. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
Liao GJ; Clark AS; Schubert EK; Mankoff DA
J Nucl Med; 2016 Aug; 57(8):1269-75. PubMed ID: 27307345
[TBL] [Abstract][Full Text] [Related]
22. Utility of
Lin FI; Gonzalez EM; Kummar S; Do K; Shih J; Adler S; Kurdziel KA; Ton A; Turkbey B; Jacobs PM; Bhattacharyya S; Chen AP; Collins JM; Doroshow JH; Choyke PL; Lindenberg ML
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):500-508. PubMed ID: 27872957
[TBL] [Abstract][Full Text] [Related]
23. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
Goodman K; Abel MK; Lawhn-Heath C; Molina-Vega J; Jones EF; Mukhtar RA
Surg Oncol Clin N Am; 2022 Oct; 31(4):569-579. PubMed ID: 36243494
[No Abstract] [Full Text] [Related]
24. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
Kurland BF; Peterson LM; Lee JH; Linden HM; Schubert EK; Dunnwald LK; Link JM; Krohn KA; Mankoff DA
J Nucl Med; 2011 Oct; 52(10):1541-9. PubMed ID: 21903739
[TBL] [Abstract][Full Text] [Related]
25. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
[TBL] [Abstract][Full Text] [Related]
26. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
[TBL] [Abstract][Full Text] [Related]
27. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
28. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA
J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724
[TBL] [Abstract][Full Text] [Related]
29. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
[TBL] [Abstract][Full Text] [Related]
30.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
31. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA
J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268
[TBL] [Abstract][Full Text] [Related]
32. Comparison of diagnostic sensitivity of [
Chae SY; Son HJ; Lee DY; Shin E; Oh JS; Seo SY; Baek S; Kim JY; Na SJ; Moon DH
EJNMMI Res; 2020 May; 10(1):54. PubMed ID: 32448947
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
34. Can
Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
[TBL] [Abstract][Full Text] [Related]
35.
Wang Y; Ayres KL; Goldman DA; Dickler MN; Bardia A; Mayer IA; Winer E; Fredrickson J; Arteaga CL; Baselga J; Manning HC; Mahmood U; Ulaner GA
Clin Cancer Res; 2017 Jun; 23(12):3053-3060. PubMed ID: 28011460
[No Abstract] [Full Text] [Related]
36. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
37. 18F-FES PET/CT for Characterization of Brain and Leptomeningeal Metastasis in Double Primary Cancer Patient.
Lee Y; Yoo IR; Ha S
Clin Nucl Med; 2022 Aug; 47(8):e554-e556. PubMed ID: 35797633
[TBL] [Abstract][Full Text] [Related]
38. 18F-Fluoroestradiol PET in the evaluation of probable oligometastatic breast cancer.
Denton M; Taubman K; Sutherland T
J Med Imaging Radiat Oncol; 2021 Jun; 65(3):333-334. PubMed ID: 33369181
[TBL] [Abstract][Full Text] [Related]
39. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.
Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ
J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of tumour heterogeneity by
Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
